In biotechnology, where uncertainty is routine, the ability to know when to change course is a critical leadership skill. That is the view of Philip Ashton-Rickardt, Managing Director and Chief Scientific Officer at BE Therapeutics, who has spent more than three decades in academic research, biotech entrepreneurship, and R&D leadership. His career includes professorships at the University of Chicago and Imperial College London, founding Smith Therapeutics, serving as Chief Scientific Officer at Sigilon Therapeutics, advising companies through Flagship Pioneering, and helping build Halyard Therapeutics and BE Therapeutics.
Ashton-Rickardt emphasizes that commitment to an idea can easily become attachment to it. "You have to separate attachment to the idea from attachment to the problem," he said. "If the problem is important, there may be several ways to approach it." In biotech, where scientific programs often evolve as new data emerge, a hypothesis that looked promising early on may need to be adjusted, narrowed, or abandoned entirely. For Ashton-Rickardt, changing direction does not automatically mean failure; rather, it can indicate that the team has learned enough to make a better decision. "Flexibility is important because changing your approach is not necessarily an admission that you failed," he said. "Sometimes it is evidence that you learned something."
A key challenge for scientific leaders is providing direction without creating false certainty. Researchers, executives, investors, and teams often need decisions before all questions are answered, creating pressure to sound more certain than the evidence justifies. Ashton-Rickardt advocates for clarity about what is known, what remains uncertain, and what would cause a decision to change. "There is a difference between providing direction and pretending to know the future," he said. "In biotech, there are simply too many unknowns." This transparency, he believes, can strengthen confidence by encouraging teams to raise concerns, question assumptions, and share evidence that challenges the current plan.
Curiosity is another quality Ashton-Rickardt values. Raised in a working-class family in the UK, he worked his way through university and into academic science before leaving a long-established academic career to return to Boston and start a biotech company. That transition required learning a new operating environment while drawing on years of scientific experience. He has since moved between startups, established biotech companies, research organizations, and investment-backed environments. "The people I enjoy working with tend to ask good questions, even when those questions make the project more complicated," he said. He also believes leaders should admit what they do not know; strong scientific thinking often shows up in the ability to explain what evidence would change one's mind.
Ashton-Rickardt's current work focuses on engineered cell therapies and treatments for neurological and other serious diseases. At BE Therapeutics and Halyard Therapeutics, where he is co-founder and Chief Scientific Officer, he translates complex scientific ideas into programs that can move forward. "The goal is not to prove that your first idea was right," he said. "The goal is to solve an important problem." For scientists and biotech leaders, that distinction can shape how teams run experiments and how companies decide where to invest time and resources. It can also make scientific organizations more adaptable at a time when new tools, new data, and new therapeutic approaches continue to change what is possible.
